Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 4
2014 3
2015 1
2016 5
2017 3
2018 2
2019 1
2020 2
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS, Schmittnaegel M, Rigamonti N, Pais-Ferreira D, Mueller P, Buchi M, Ooi CH, Kreuzaler M, Hirschmann P, Guichard A, Rieder N, Bill R, Herting F, Kienast Y, Dirnhofer S, Klein C, Hoves S, Ries CH, Corse E, De Palma M, Zippelius A. Kashyap AS, et al. Among authors: herting f. Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):541-551. doi: 10.1073/pnas.1902145116. Epub 2019 Dec 30. Proc Natl Acad Sci U S A. 2020. PMID: 31889004 Free PMC article.
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.
Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C. Herter S, et al. Among authors: herting f. Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19. Mol Cancer Ther. 2013. PMID: 23873847 Free article.
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.
Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P. Brünker P, et al. Among authors: herting f. Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1. Mol Cancer Ther. 2016. PMID: 27037412 Free article.
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.
Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G. Kollmorgen G, et al. Among authors: herting f. Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7. Sci Rep. 2017. PMID: 29273809 Free PMC article.
An integrated approach to quantitative modelling in angiogenesis research.
Connor AJ, Nowak RP, Lorenzon E, Thomas M, Herting F, Hoert S, Quaiser T, Shochat E, Pitt-Francis J, Cooper J, Maini PK, Byrne HM. Connor AJ, et al. Among authors: herting f. J R Soc Interface. 2015 Sep 6;12(110):0546. doi: 10.1098/rsif.2015.0546. J R Soc Interface. 2015. PMID: 26289655 Free PMC article.
22 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page